SLC5A2 and chronic kidney disease: The clinical outcomes of the patients with/without DM, HF and CKD who received the SGLT2 inhibitors empagliflozin, dapagliflozin, canagliflozin, sotagliflozin and ertugliflozin are listed in Table 2.